

## Curriculum Vitae

PERSONAL DATA	
Name	Michele Ciboddo
Date/place of birth	09/18/1989 / Segrate (MI)
Citizenship	Italian
Work address	Fondazione IRCCS Policlinico San Matteo - V.le Golgi 19, 27100 Pavia
Phone number	<a href="tel:+3903214854134">+16174854134</a>
e-mail address	<a href="mailto:michele.ciboddo@gmail.com">michele.ciboddo@gmail.com</a>



EDUCATION			
Name of Institution	Location (City, Country)	Degree	Year
University of Pavia	Pavia, Italy	Hematology Specialization	Ongoing
University of the study of Milan	Milan, Italy	Medical School Degree	2014

RESEARCH EXPERIENCE		
From - To	Position	Research activity
2017-ongoing	Collaboration project University of Pavia and Harvard Medical School Boston, USA	Study the mechanism of resistance to JAK2 inhibitors through the use of the genetical engineering technique of Whole Genome CRISPR Screen.
2016-ongoing	Residency Programm in University of Pavia, Italy	Collaborating in clinical research in Philadelphia Negative Myeloproliferative Neoplasms.
2014-2015	Volunteer in Functional Genomic of Cancer IRCCS Ospedale San Raffaele, Milano, Italy	Elucidating the molecular advantage of the loss of UTX (KDM6A) in Multiple Myeloma.
2012-2014	Internship in Human Genetics IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy	Taking part to research about epigenetics in several congenital and neoplastic conditions. His expertise was especially developed in brain cancer (Glioblastoma Multiforme) and Myelofibrosis.

TECHNICAL SKILLS AND COMPETENCES
<p>Dr. Michele Ciboddo's research is mainly focused in understanding the molecular pathogenesis of neoplastic conditions. He is involved in a collaboration project with Harvard Medical School and Brigham and Womens' Hospital. Using the Whole genome CRISPR screen, a new genetical engineering technique, he is trying to develop a new combination treatments for patients affected by myelofibrosis, that can further improve their outcome under Ruxolitinib treatment. He is also exploring other phenotype driven by CALR mutation. His research can help in understanding the mechanistic role of the mutation in developing the malignant transformation and can help in finding new molecular vulnerabilities. Dr. Michele Ciboddo has laboratory experience in terms of cell culture, infection with retro and lentivirus, molecular biology (PCR, Western Blotting, Immunofluorescence, FACS and others) and some metabolism Assay (Seahorse, Lactate Assay kit and others).</p> <p>Dr. Michele Ciboddo is also training in the clinical research of Myeloproliferative Neoplasms, with Prof. Elisa Rumi as mentor, and in clinical activity as Resident in Hematology in University of Pavia. He is also involved as sub-investigator in several translational research trial.</p>

PUBLICATIONS

1.	Oncotarget. 2017 Oct 6;8(60):101735-101744 Rumi E, Boveri E, Bellini M, Pietra D, Ferretti VV, Sant'Antonio E, Cavalloni C, Casetti IC, Roncoroni E, <b>Ciboddo M</b> , Benvenuti P, Landini B, Fugazza E, Troletti D, Astori C, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.
2.	Oncotarget. 2017 May 16;8(20):33416-33421 Cavalloni C, Rumi E, Ferretti VV, Pietra D, Roncoroni E, Bellini M, <b>Ciboddo M</b> , Casetti IC, Landini B, Fugazza E, Troletti D, Astori C, Cazzola M.
3.	Leuk Res. 2015 Feb;39(2):236-41. Augello C, Gianelli U, Falcone R, Tabano S, Savi F, Bonaparte E, <b>Ciboddo M</b> , Paganini L, Parafioriti A, Ricca D, Lonati S, Cattaneo D, Fracchiolla NS, Iurlo A, Cortezzi A, Bosari S, Miozzo M, Sirchia SM.